Retro Biosciences' RTR242 Phase 1 Trial and Human Mimetic Evidence
Thumbnail from YouTube. Playing loads the YouTube player.
History & recommendationsOff
Keep recently viewed content on this browser. Your history stays on this device and is never sent to Harbor. Videos you play can also help order related video recommendations.
Open saved items & history →At a glance
Automatic summary · not editorially reviewedThe description says Retro Biosciences, seeded with $180M from Sam Altman, has entered a first-in-human Phase 1 trial of RTR242, an oral small molecule aimed at restoring lysosomal acidification and autophagy; it also reviews human randomized trials of spermidine and Urolithin A. [1]
The description reports a first-in-human Phase 1 safety and pharmacokinetic study of RTR242 in healthy volunteers in Adelaide, with n = 76–108 and Alzheimer's disease as the target indication. [1]
The description says lysosomal recycling becomes less efficient after age 50 and names loss of acidity and cytoplasmic trapping of TFEB as bottlenecks. [1]
The description says it reviews randomized human trials of spermidine (SmartAge) and Urolithin A (ATLAS) but does not state their results. [1]
RTR242 trial in healthy volunteers in Adelaide
The description reports a first-in-human Phase 1 study of RTR242 in Adelaide, Australia, described as a single- and multiple-ascending-dose safety and pharmacokinetic study in healthy volunteers, with n = 76–108. The stated target indication is Alzheimer's disease. RTR242 is described as an oral small molecule designed to restore lysosomal acidification without upstream mTOR inhibition. The description also mentions pharmacological challenges of blood-brain barrier delivery for Alzheimer's disease. [1]
Aging lysosomes: acidity loss and TFEB trapping
According to the description, every cell continuously produces metabolic waste and clears debris through autophagy. As people age past 50, lysosomal recycling is said to become less efficient, driving proteostatic stress and cellular decline in non-dividing neurons and cardiomyocytes. The description names two mechanical bottlenecks in aging lysosomes: loss of acidity and cytoplasmic trapping of TFEB. These are presented as proposed mechanisms, not as established causes of human disease. [1]
Spermidine and Urolithin A in randomized human trials
The description says it reviews what randomized human trials show for dietary mimetics such as spermidine (the SmartAge trial) and Urolithin A (the ATLAS trial). It cites a spermidine trial in older adults with subjective cognitive decline and Urolithin A trials in older and middle-aged adults. The description does not state the results of these trials, so no benefit can be inferred from it. It also mentions lifestyle strategies such as Zone 2 exercise and fasting, without reporting outcomes. [1]
Context & limits
Only the video description was available; the video and transcript were not reviewed. Trial details, mechanisms and cited studies come from the description, which does not report outcomes for the spermidine or Urolithin A trials. The description includes supplement discount links and a medical disclaimer; it is not medical advice.
Based on the creator’s description; the full video and transcript were not analyzed.
Quoted passages in the original language
First-in-human SAD/MAD safety and PK study
loss of acidity and cytoplasmic trapping of
the SmartAge trial
About this video
Creator description · original textText language: English
Modern Healthspan · 13 min · Source published: 2026-10-08
Added to Harbor: 10/23/2026
Original on YouTube ↗Automatically categorized source. Creator statements are not an independent evidence review or personal medical guidance.